[ad_1]
On October 8, Eli Lilly Pharmaceuticals (LLY.US) announced that it had signed an agreement with the Gates Foundation to help low- and middle-income countries access potential new corona antibody therapies.Eli Lilly said that commercial production will begin in April 2021 at the FUJIFILM Diosynth Biotechnologies plant in Denmark.
access:
Alibaba Cloud Launches Special Session for Colleges and Universities: 0 Yuan Entry to Cloud Computing Experience Rapid Implementation of Enterprise Projects
Eli Lilly has begun transferring production technology, because his antibody therapy is expected to be approved by regulatory authorities. In order to offer innovative products globally as soon as possible, the company will provide a certain amount of antibodies to other low-income countries in April 2021 Currently, therapeutic products are awaiting approval from regulatory agencies. Eli Lilly and its partners will remain responsible for product development.
Eli Lilly has two new corona antibody therapies in development. Among them, the main antibody LY-CoV555 developed in cooperation with the biotech company AbCellera entered phase III trials in early August. This is the first potential antibody treatment for new coronary pneumonia to have advanced in human trials. .
Another new coronavirus antibody therapy offered by Eli Lilly is the novel coronavirus neutralizing antibody JS016 (LY-CoV016) in cooperation with Junshi Bio (1877.HK, 688180.SH).
On October 7, Junshi Biotech announced that its partner Eli Lilly announced the positive effects of the new coronavirus neutralizing antibody JS016 (LY-CoV016) and the combination therapy LY-CoV555 in the treatment of newly diagnosed patients with mild to moderate coronary pneumonia. (COVID-19). Provisional data.
The results showed that the combination therapy consisting of two new coronavirus neutralizing antibodies lowered viral load, relieved symptoms, and reduced hospitalizations and emergency department visits related to new coronary pneumonia.
On October 8, Junshi Bio-Hong Kong shares rose 11.27% to close at 55.8 Hong Kong dollars.
Eli Lilly announced on October 7 that he plans to apply for an emergency use authorization (EUA) for combination therapy in patients with mild to moderate new coronary pneumonia in November 2020.
The aforementioned agreement on the provision of antibody therapy for low- and middle-income countries is reported to be part of the COVID-19 Therapeutic Accelerator. Therapeutics Accelerator is a project started by the Gates Foundation and others.
As part of the plan, Eli Lilly’s partners, including AbCellera, Junshi Bio and Columbia University, agreed to waive royalties for sales in low- and middle-income countries.
